ijms-logo

Journal Browser

Journal Browser

Special Issue "Molecular Determinants of Prostate Cancer Metastasis"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editor

Dr. Josiah Ochieng
E-Mail
Guest Editor
Meharry Medical College, Nashville, TN, USA
Interests: molecular; determinants; cancer metastasis; fetuin-A; galectin-3; prostate cancer; breast cancer

Special Issue Information

The metastatic process in prostate cancer (PCa), just like in other malignancies, is indeed complex, involving numerous signaling molecules. To complicate matters, stromal cells in the tumor microenvironment also participate actively in the process. For the last 30 years or more, key proteins that were thought to be part of a unifying theme in the process such as matrix metalloproteinase have been defined. However, despite the intense global efforts to design effective inhibitors for these enzymes to combat metastasis, little was accomplished. Prostate cancer, however, unlike other tumors such as pancreatic cancer, grows more slowly and can be divided into indolent and aggressive subtypes. The aggressive subtypes arising from prostate cancer stem cells are normally unresponsive to hormonal therapy. These have the propensity to grow rapidly and metastasize. Therefore, there is an urgent need to uncover the unifying process or processes that provide metastatic advantage to the aggressive subtypes of PCa.

Dr. Josiah Ochieng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate
  • stem
  • aggressive
  • indolent
  • metastasis
  • hormonal
  • therapy
  • stromal
  • microenvironment
  • subtype

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
Int. J. Mol. Sci. 2021, 22(11), 5515; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22115515 - 24 May 2021
Cited by 1 | Viewed by 777
Abstract
Metastatic prostate cancer is the most common cancer in males and the fifth cause of cancer mortality worldwide. Despite the major progress in this field, leading to the approval of novel anti-androgens, the prognosis is still poor. A significant number of patients acquire [...] Read more.
Metastatic prostate cancer is the most common cancer in males and the fifth cause of cancer mortality worldwide. Despite the major progress in this field, leading to the approval of novel anti-androgens, the prognosis is still poor. A significant number of patients acquire an androgen receptor splice variant 7 (AR-V7), which is constitutively activated and lacks the ligand-binding domain (LBD) while maintaining the nuclear localization signal and DNA-binding domain (DBD). This conformational change, even in the absence of the ligand, allows its retention within the nucleus, where it acts as a transcription factor repressing crucial tumor suppressor genes. AR-V7 is an important oncogenic driver and plays a role as an early diagnostic and prognostic marker, as well as a therapeutic target for antagonists such as niclosamide and TAS3681. Anti-AR-V7 drugs have shown promise in recent clinical investigations on this subset of patients. This mini-review focuses on the relevance of AR-V7 in the clinical manifestations of castration-resistant prostate cancer (CRPC) and summarizes redemptive therapeutic strategies. Full article
(This article belongs to the Special Issue Molecular Determinants of Prostate Cancer Metastasis)
Show Figures

Figure 1

Back to TopTop